Volatile Organic Compounds in Uremia

Background Although “uremic fetor” has long been felt to be diagnostic of renal failure, the compounds exhaled in uremia remain largely unknown so far. The present work investigates whether breath analysis by ion mobility spectrometry can be used for the identification of volatile organic compounds retained in uremia. Methods Breath analysis was performed in 28 adults with an eGFR ≥60 ml/min per 1.73 m2, 26 adults with chronic renal failure corresponding to an eGFR of 10–59 ml/min per 1.73 m2, and 28 adults with end-stage renal disease (ESRD) before and after a hemodialysis session. Breath analysis was performed by ion mobility spectrometryafter gas-chromatographic preseparation. Identification of the compounds of interest was performed by thermal desorption gas chromatography/mass spectrometry. Results Breath analyses revealed significant differences in the spectra of patients with and without renal failure. Thirteen compounds were chosen for further evaluation. Some compounds including hydroxyacetone, 3-hydroxy-2-butanone and ammonia accumulated with decreasing renal function and were eliminated by dialysis. The concentrations of these compounds allowed a significant differentiation between healthy, chronic renal failure with an eGFR of 10–59 ml/min, and ESRD (p<0.05 each). Other compounds including 4-heptanal, 4-heptanone, and 2-heptanone preferentially or exclusively occurred in patients undergoing hemodialysis. Conclusion Impairment of renal function induces a characteristic fingerprint of volatile compounds in the breath. The technique of ion mobility spectrometry can be used for the identification of lipophilic uremic retention molecules.

[1]  H H Hill,et al.  Ion mobility spectrometry. , 1990, Analytical chemistry.

[2]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[3]  Kevin Gleeson,et al.  Detection of lung cancer with volatile markers in the breath. , 2003, Chest.

[4]  Jörg Ingo Baumbach,et al.  Peak comparison in MCC/IMS-data—searching for potential biomarkers in human breath data , 2008 .

[5]  Tim W. Nattkemper,et al.  Web2.0 paves new ways for collaborative and exploratory analysis of chemical compounds in spectrometry data , 2011, J. Integr. Bioinform..

[6]  L R Narasimhan,et al.  Correlation of breath ammonia with blood urea nitrogen and creatinine during hemodialysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Vautz,et al.  Novel design for drift tubes in ion mobility spectrometry for optimised resolution of peak clusters , 2011 .

[8]  A. Bunkowski,et al.  Software tool for coupling chromatographic total ion current dependencies of GC/MSD and MCC/IMS , 2010 .

[9]  W. Vautz,et al.  Breath sampling control for medical application , 2010 .

[10]  W. Vautz,et al.  Breath analysis—performance and potential of ion mobility spectrometry , 2009, Journal of breath research.

[11]  R. Vanholder,et al.  PROGRESS IN UREMIC TOXIN RESEARCH: Protein‐Bound Toxins—Update 2009 , 2009, Seminars in dialysis.

[12]  S. Shiratori,et al.  In vitro effects of diacerein on NO production by chondrocytes in response to proinflammatory mediators. , 2008 .

[13]  G. Sun,et al.  Quantitative breath analysis of volatile organic compounds of lung cancer patients. , 2010, Lung cancer.

[14]  A. B. Robinson,et al.  Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Risler,et al.  4-Heptanone is a metabolite of the plasticizer di(2-ethylhexyl) phthalate (DEHP) in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  R. Doty,et al.  Biochemical profile or uremic breath. , 1977, The New England journal of medicine.

[17]  Tao Qin,et al.  The Screening of Volatile Markers for Hepatocellular Carcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[18]  R. Milne,et al.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.